Impel Pharmaceuticals
Entity

  • Impel Pharmaceuticals

    Created in 2008
  • BETA

    Up & running (A)
    Existing signals show a regular activity

  • Social networks

    369 421 9,567

  • Activities

    healthtech deeptech biotech

  • Technologies

    Synthetic Biology

  • Entity types

    Startup

  • Location

    Waterfront Research Center, 201 Elliott Ave W, Seattle, WA 98119, USA

    Seattle

    United States of America

  • Employees

    Scale: 51-200

    Estimated: 47

  • Engaged corporates

    1
    1 1

  • Added in Motherbase

    4 years, 10 months ago
Description
  • Value proposition

    Developing life-changing, innovative therapies for diseases with unmet needs

    Impel Pharmaceuticals is focused on developing and providing transformative therapies for people suffering from diseases with high unmet needs across various disease areas in addition to the central nervous system (CNS), through the pioneering of an optimized approach to drug delivery. We offer and develop treatments that pair the Company’s proprietary Precision Olfactory Delivery (POD®) technology with well-established therapeutics.

    Intranasal Drug Delivery, Migraine, Parkinson's Disease, CNS Therapeutics, and Autism

  • Home | Impel Pharmaceuticals

    Impel Pharmaceuticals specializes in Precision Olfactory Delivery (POD) nasal devices for Alzheimer's, migraine, and other central nervous system diseases.

    • https://impelpharma.com/
Corporate interactions BETA
Corporate TypeTweets Articles
KKR
KKR
Startup accelerator & VC, Financial Services
KKR
Startup accelerator & VC, Financial Services 		Capitalistic
Partnership
Not event

6 Dec 2018


Similar entities
Last news
Show all articles
Social network dynamics